First Choice Healthcare Solutions and Westin Acquisition Corp Announce \$650 Million Business Combination to Form Wellgevity 360
Key Highlights of the Transaction
- Strategic Rebrand: First Choice Healthcare Solutions, Inc. (FCHS) will rebrand as Wellgevity 360, aiming to become a publicly traded, next-generation healthcare and wellness platform focused on longevity, preventative care, and personalized, biology-driven treatment solutions.
- Valuation: The transaction values First Choice Healthcare at a pro forma enterprise value of approximately \$650 million.
- Market Opportunity: The U.S. wellness economy is valued at \$2.1 trillion and is growing at an annual rate of 7.9%. U.S. per capita wellness spending surpassed \$6,000 in 2024, with the sector accounting for over 7% of the nation’s GDP.
- Post-Combination Listing: The combined company is expected to trade on Nasdaq, giving investors broader access and liquidity.
- Expected Close: The transaction is anticipated to close in the fourth quarter of 2026, subject to regulatory and shareholder approvals as well as other customary closing conditions.
Details of the Proposed Transaction
Under the definitive agreement, Westin Acquisition Corp (Nasdaq: WSTN, WSTNR, WSTNU), a Cayman Islands SPAC, will domesticate to Nevada and become “PubCo.” A wholly owned subsidiary of PubCo will merge with and into First Choice, with First Choice surviving as a wholly owned subsidiary of PubCo. This structure is designed to facilitate access to the U.S. public markets and support rapid growth and capital investment.
Business Model and Market Rationale
- Expanding Footprint: The combined company will focus on developing and operating functional health, longevity, and regenerative medicine clinics, positioning itself at the intersection of primary care, wellness, and advanced therapeutics.
- Industry Trends: The global wellness economy hit a record \$6.8 trillion and is projected to reach \$9.8 trillion by 2029. Millennials and Gen Z are driving demand for “prejuvenation,” expanding med-spas and aesthetic clinics into full-service longevity and screening centers.
- Revenue Model: Longevity medicine emphasizes cash-pay models, reducing reliance on insurance, and offers predictable recurring revenue through membership programs. The business targets high-income demographics, compounding revenue potential per patient.
- Innovation: The company plans to invest in emerging technologies such as AI-driven diagnostics, genomics, biomarkers, and senolytics to drive precision medicine and personalized health optimization.
Leadership Commentary
Mr. Kok Peng Na, Chairman/CEO of Westin: “The merger reflects our commitment to partnering with a company with an innovative healthcare platform, experienced management team and significant growth potential. We believe the Company is well positioned to capitalize on the growing demand for primary care, wellness and regenerative medicine services, and that this proposed transaction will provide the resources, public market access, and strategic flexibility needed to support its next phase of growth.”
Mr. Lance Friedman, CEO of First Choice Healthcare Solutions, Inc.: “This business combination marks a transformative milestone for First Choice as we capitalize on the accelerating demand for longevity and functional medicine. By combining our clinical model with Westin’s public market access, we expect to be able to scale our operations rapidly, invest in cutting-edge health technologies, and expand our services to a broader patient base seeking to optimize their health span and lifespan.”
Transaction Process and Next Steps
- The boards of both Westin and First Choice have unanimously approved the transaction.
- Completion is subject to regulatory approvals, shareholder votes, effectiveness of a registration statement with the SEC, and Nasdaq listing approval.
- Details regarding transaction proceeds, sources and uses of funds, and pro forma ownership will be included in the registration statement and other materials to be filed with the SEC.
- The companies may seek additional financing arrangements in connection with the transaction.
Advisors
- Legal Advisors to Westin: Celine & Partners, PLLC and Ogier
- U.S. Securities Counsel to First Choice: Sichenzia Ross Ference Carmel LLP
- Financial Advisor to First Choice: Geneva Capital Pte. Ltd. (GCCPL)
What Shareholders Need to Know (Potentially Price Sensitive)
- This is a major strategic transaction that could significantly increase the scale, visibility, and valuation of First Choice as it transitions to Wellgevity 360 and targets the high-growth wellness and longevity markets.
- Shareholders must vote to approve the transaction; the outcome could have a direct impact on share value and market perception.
- The transaction will provide public market access and potential new sources of capital, which may accelerate growth and innovation, but it also brings integration, execution, and regulatory risks.
- Key risks include the possibility of the transaction not closing due to regulatory, legal, or shareholder hurdles, as well as market and competitive risks in the rapidly evolving healthcare and wellness sector.
Next Steps for Investors
- Investors and security holders are urged to read all relevant SEC filings, including the registration statement on Form F-4, proxy statement/prospectus, and any risk factor disclosures, as they become available.
- Free copies of these documents will be made available at www.sec.gov and upon request from Westin Acquisition Corp.
- Shareholders should monitor upcoming shareholder meetings and vote on the proposed business combination.
Cautionary Notes
This press release contains forward-looking statements subject to significant risks and uncertainties, including the ability to close the transaction, obtain necessary approvals, and realize anticipated benefits. Actual results may differ materially from those projected. Investors are advised to review all SEC filings for a full list of risk factors and to exercise caution when making investment decisions.
Disclaimer: This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. It should not be relied upon as the basis for any investment decision. Readers are advised to consult professional advisors and review all relevant SEC filings before making any investment related to this transaction. The information herein may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ. The companies involved undertake no obligation to update or revise the information presented except as required by law.
